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Abstract: We conducted a systematic review of adherence support programs involving doctors 
and pharmacists. We searched MEDLINE®, Embase, International Pharmaceutical Abstracts, 
PsycINFO®, and CINAHL using the keywords “pharmacist” or “doctor” and “adhere*” or 
“ compli*” and “randomized controlled trials”. We found 89 studies involving pharmacists; in 
contrast, only 14 studies involved doctors. The roles of pharmacists and doctors ranged from 
providing education and counseling to adjusting treatment. Most interventions that specified a 
patient group were carried out with patients with chronic conditions (n=79) and only six included 
short-term treatments. The majority of interventions improved adherence and clinical outcomes to 
some extent, although the size of effect size was sometimes small. Resource utilization (eg, hos-
pitalization rates, visits to doctors) did not change in the majority of studies that reported it. Few 
studies included cost analyses. All but one study had high risk of performance bias due to the 
nature of the interventions, which made it impossible to blind the participants. The majority of 
studies did not report tailoring the interventions to patient needs and the vast majority of papers 
did not report taking a concordant patient-centered approach or considering patients’ own views 
and experiences when providing adherence support. In addition, the majority of studies did not 
describe training for the health care professionals involved in providing adherence support. Pro-
viding training for doctors and pharmacists to take a more patient-centered concordant approach 
would be expected to increase the effectiveness of adherence support further.
Keywords: interventions, patient views, patient experiences, patient-centered approach, 
resource utilization
Introduction to patient adherence  
support and programs
One of the biggest challenges in health care worldwide is to ensure that patients are 
both willing and able to take their treatments as prescribed, and that they persist in 
doing so over the designated amount of time. When they do not do this, it is most often 
referred to as “treatment nonadherence” or “treatment noncompliance”, and the conse-
quences can be severe. Nonadherence to appropriately prescribed treatments may lead 
to reduced clinical benefit and increased risk of morbidity and mortality.1 For example, 
it has been estimated that nonadherence is responsible for 48% of asthma deaths, an 
80% increased risk of death in diabetes and a 3.8-fold increased risk of death in the 
year following a heart attack.2 The related economic burden on health care systems is 
significant. In the UK, the cost of unused and unwanted medicines has been estimated 
to reach £300 million per year,3 and, in the USA, nonadherence has been estimated to 
cost the US health care system US$310 billion (note US billion =109) annually.4
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Nonadherence is prevalent in all disease categories and 
similar rates of nonadherence are found in chronic conditions 
such as diabetes (33%) and skin disorders (23%) as in life-
threatening conditions such as cancer (20%) and end-stage 
renal disease (30%).5 However, rates may vary between 
patients as well as within individual patients across different 
treatments and over time. The rate of nonadherence that is 
clinically significant also varies between diseases. Typically, 
lifestyle recommendations such as diet (average percentage 
of patients that were nonadherent across studies 41%) and 
exercise (average percentage of patients nonadherent 28%) 
display more adherence challenges than pharmaceutical 
medicines (average percentage of patients that were non-
adherent 21%).5 Asymptomatic patients have been found to 
be less adherent than symptomatic patients in, for example, 
HIV.6 It is important to point out that differing adherence 
definitions and measurements used across studies also influ-
ence the adherence rates captured.
The reasons for nonadherence are numerous and multifac-
eted, and the patients’ relationship and communication with 
their health care providers are key factors that influence both 
their motivation and their ability to adhere.1 The patient may 
decide not to take their treatment as prescribed (“intentional 
nonadherence”) for several different reasons. For example, 
the patient may experience side-effects that they are not 
prepared to tolerate or may have concerns over the long-term 
effects of taking the medication, while other patients may not 
fully appreciate the necessity or effectiveness of the medica-
tion to manage their condition.1 Other patients may not be 
able to take their treatment as prescribed, even though they 
intend to do so (“unintentional nonadherence”).  Forgetting 
is the most common reason patients’ give for missing doses 
unintentionally, but problems such as difficulties with dex-
terity and swallowing, reduced access to medication, and 
high prescription co-payments can also hinder treatment 
 adherence.1 It is worth bearing in mind that forgetting is 
an example of unintentional nonadherence that might be 
influenced by intentional factors, such as perceived need for 
treatment and concerns about treatment.7
Both international and national policy drivers, such as the 
World Health Organization8 and National Institute for Health 
and Care Excellence1 in the UK, have called for increased 
patient involvement in treatment decisions to improve adher-
ence and health care outcomes. The term “concordance” 
can be used to emphasize the shared decision-making process 
between patient and health care provider that should ideally 
be achieved when prescribing treatments. A scoping review of 
concordance, adherence, and compliance in medicine taking 
noted that concordance initially focused on the consultation 
process, in which doctor and patient agree therapeutic deci-
sions that incorporate their respective views and moved to a 
wider concept that stretches from prescribing communication 
to patient support in medicine taking. In the concordance 
model, a decision not to take a medicine is an acceptable 
and good outcome.9,10
In addition, numerous adherence support programs have 
been developed over the years. Key criteria for success are 
that interventions are appropriate for implementation in 
practice and that they are cost-effective. To ensure robust 
development, implementation, and evaluation of interven-
tions, it has been recommended that development is theory 
driven11 and that the behavioral-change techniques (BCTs) 
that are used is clearly defined.12
A number of large-scale reviews have evaluated the 
evidence around adherence support programs. For example, 
Haynes et al13 and Kripalani et al14 reviewed randomized 
controlled trials that measured both adherence and clinical 
outcome. Haynes et al13 found 44% and Kripanali et al14 
found 54% of interventions successful at increasing adher-
ence. However, Haynes et al13 noted that “even with the 
most effective methods for long-term treatments, improve-
ments in drug use or health were not large”. Kripalani et al14 
and Haynes et al13 concluded that complex interventions 
were more likely to be effective, for example, by includ-
ing  combinations of more convenient care, information, 
reminders, self-monitoring, reinforcement, counseling, 
family therapy, psychological therapy, crisis intervention, 
manual telephone follow-up, and supportive care (although 
they could not determine the relative importance of the 
 individual components). There was also no consensus 
regarding whether motivational, behavioral, or combined 
approaches were preferable.
The literature has not been able to provide guidance 
regarding what specific theoretical models and BCTs are 
needed to improve the effectiveness of adherence interven-
tions, but there are some indications of factors that may 
increase effectiveness. Kripalani et al14 concluded that 
behavioral interventions that reduced the dosing demands 
of therapies consistently improved adherence with a large 
effect size. Haynes et al13 argued that interventions delivered 
by allied health care professionals (HCPs) such as nurses 
and pharmacists were worthy of future research. In addition, 
others have found that tailoring interventions to individual 
patients’ needs, rather than using a “one-size-fits-all” 
approach, is likely to be more effective.15 Interventions that 
are tailored to individual needs can, for example, distinguish 
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between a patient’s lack of motivation to take medication 
and practical barriers to taking medication, as well as 
address an individual’s unique mix of factors in order to 
improve adherence. Lastly, a recent meta-analysis found 
that cognitive-based BCTs are effective at improving adher-
ence, can be effectively delivered by routine HCPs, and can 
have effects that go beyond those achieved by educational 
or behavioral interventions.16
Some more recent reviews have focused on particular 
modes of delivery. For example, Rubio-Valera et al17 and 
Morgado et al18 reviewed pharmacist-led adherence sup-
port programs for patients prescribed antidepressants and 
antihypertensives, respectively, and these interventions were 
deemed promising and worthy of further study. Pharmacists 
may be considered particularly suited to deliver adherence 
interventions given their responsibility to monitor and opti-
mize patients’ pharmacological treatment as part of providing 
pharmaceutical care.19 Cutrona et al20 reviewed interventions 
for cardiovascular medication in which the patient’s  doctor 
was involved, but the interventions appeared to be less effec-
tive when a doctor was involved than when other HCPs were 
involved.20
Due to the promising findings regarding pharmacist-led 
interventions from these disease-specific reviews, one of 
the aims of the current review was to expand the scope and 
review the evidence regarding pharmacist-led  adherence 
support programs across diseases categories. Second, 
despite the negative impact of physician involvement in 
adherence support programs for cardiovascular medications 
found by Cutrona et al,20 it was deemed important to include 
a wider search for evidence from such interventions in other 
populations. The role of nurses was beyond the scope of 
this project.
Methods
Search strategy
We carried out a systematic review to evaluate delivery 
of patient adherence support involving pharmacists and/or 
 doctors. We included evidence related to all aspects of patient 
adherence (eg, adherence to medication, diet, lifestyle 
changes, screening procedures).
SG and LE developed a search strategy and performed 
an electronic search of the following databases: MEDLINE® 
(1946 to September 6, 2013), Embase (1980 to August 2013), 
International Pharmaceutical Abstracts (1970 to August 
2013), PsycINFO® (1806 to the first week of  September 
2013), and CINAHL (September 9, 2013). We used the 
 keywords “pharmacist” or “doctor” or “physician” and 
“adhere*” or “compli*” and “randomized controlled  trials”. 
MA also hand searched the bibliographies of included papers 
and obtained the full text of any original studies that poten-
tially met the inclusion criteria.
Inclusion and exclusion criteria
Inclusion criterion
The inclusion criterion was RCTs of interventions to improve 
adherence in which pharmacists and/or doctors had a defined 
role in terms of delivery. All countries and settings were 
included.
exclusion criteria
The exclusion criteria were: study designs other than 
RCTs, interventions without a defined role for pharmacists 
and/or doctors, papers not published in English, conference 
abstracts, and protocols only.
Screening and data extraction
All database search results were combined into a Reference 
Manager® (v 11; Thomson Reuters, New York, NY, USA) 
database. An electronic duplicate search was conducted using 
Reference Manager followed by a manual duplicate search. 
All duplicate papers were removed. MA then screened each 
title and abstract to determine whether the full research paper 
should be retrieved or whether it was evident it did not meet 
the inclusion criterion at that stage. SG independently screened 
a random 10% sample of abstracts to check the reliability of 
the screening process (agreement level 90%). All discrepan-
cies were resolved through discussion. MA then reviewed all 
retrieved and screened full manuscripts to determine whether 
each article met the inclusion criterion and SG independently 
reviewed a further random 10% sample of full papers to 
check reliability (agreement level 96%). MA then extracted 
data from the included articles regarding pharmacists’ and/or 
doctors’ delivery of support on patient adherence. SG then 
independently reviewed a random 10% of the data extraction 
table to check reliability (agreement level 90%).
The following data were extracted directly into electronic 
tables: study author and year, the country in which the 
research was carried out, sample size, clinical diseases of 
interest, the nature of the intervention (including whether it 
was tailored to each patient or fixed for all participants), the 
setting and the HCP involved, training for HCP, the HCP’s 
involvement in the intervention, measured outcomes, and 
the effectiveness of the intervention.
To assess the quality and the risk of biases of the included 
papers, the Cochrane Collaboration’s tool for assessing risk of 
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bias in randomized trials was used.21 MA performed a quality 
assessment of the included papers, and SG conducted a 10% 
reliability check (agreement level 94%). All discrepancies 
were resolved through discussion.
Results
Overview
A total of 1,031 abstracts were screened and 219 full-text 
articles were obtained. Of these, 103 met the inclusion 
criterion22–124 (Figure 1). Details of the included studies are 
shown in Supplementary Table S1 and Table S2.
Quality assessment
The full quality-assessment results are found in Supplemen-
tary Table S2. Of the 103 studies, 13 were found to have low 
risk of bias in all domains (selection bias, detection bias, 
attrition bias, selective reporting bias, and other bias) except 
for the risk of performance bias. Only three studies had high 
risk of bias in at least four of the six domains.25,78,83
Performance bias
All but one study had high risk of performance bias. The high 
risk of performance bias was due to the nature of the inter-
ventions, which made it impossible to blind the participants. 
The only study that did not have high risk of performance 
bias had an unclear risk, because the patients were blinded 
but the physicians were not.29
Selection bias
The risk of bias when generating the random sequence 
was low in 50 studies and high in 14 studies. In 39 papers, 
the method of generating a random sequence was not 
described, making the risk of selection bias unclear. The 
risk of selection bias when concealing the allocation 
was low in 44 studies, high in 47 studies, and unclear in 
12 studies.
Detection bias
In 26 studies, the risk of detection bias was low. In 69 studies, 
information regarding blinding of outcome measurements 
was insufficient, making the risk of detection bias unclear, 
and, in eight of the studies, the risk was high.
Attrition bias
The majority of studies had a low risk of attrition bias. 
Conversely, 17 studies were found to have a high risk of 
attrition bias, and, in 14 studies, the information provided 
was insufficient to decide the risk of attrition bias.
Selective reporting bias
In 99 studies, no selective reporting could be identified, 
indicating low risk of reporting bias. However, in one 
study, some results were only compared within the groups 
and not between them.109 In three studies (3%), data were 
incomplete.42,58,103
Number of papers after full text screening,
included in review
=103
Number of full text papers obtained
=219
• Hand searched papers
  =25
• Number of duplicates removed =626
• Number of papers excluded after abstract
  screening =837
• Conference abstracts =136
• No defined role of pharmacist or doctor =31
• Only protocol =33
• No RCT =126
• Not in English =1
• No RCT =17
• Only protocol =1
• Number of excluded papers after full text
  screening =116
• Not regarding improving patient adherence =47
• No defined role of pharmacist or doctor =50
• Not in English =63
• Not regarding improving patient adherence =448
Number of papers after duplicates
removed
=1,031
Number of papers retrieved from
electronic search
=1,657
Figure 1 Flow chart of papers identified, screened and evaluated.
Abbreviation: RCT, randomized controlled trial.
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Other bias
Other risks of bias occurred when there were differences 
between the intervention group and control group at baseline. 
This type of bias occurred in 29 studies. Examples were 
difference in age of patients declining to participate and 
those who consented,39 dropout rate,26 adherence,41,94 blood 
pressure,48,106,113 and comorbidity.48,63
Key findings
The HCP delivering the intervention
Only 14 of the interventions were delivered by 
doctors.29,35,38,53,61,64,72,87,95,96,98,110 The rest of the interventions 
were delivered by different types of pharmacists (clinical, 
hospital, community, research, senior, or unspecified).
Settings
In 52 papers, the setting was described as special clinics or prac-
tices, and, in 24 papers, the studies were carried out at hospitals. 
Eighteen studies were carried out at community pharmacies.
A total of 44 studies were carried out in the USA, with 
the remaining studies having been conducted in a range of 
international countries, including those in Europe, Africa, 
Asia, Canada, and Australia.
Clinical diseases
The most common diseases targeted in the interventions were 
hypertension (16 studies), type II diabetes (eleven studies) and 
heart failure (seven studies). In eleven studies, there was no 
specific disease group studied. Most interventions were car-
ried out with patients with chronic conditions and only a few 
included short-term treatments – for instance,  Helicobacter 
pylori-infected ulcers or other infections.24,34,57,78,108
Training received by the HCP
In the majority of studies, no additional training for the HCP 
was described (63%). However, when additional training 
was reported (37% of the studies), it included educational 
workshops on the specific disease, training on the intervention 
protocol or relevant guidelines, or interview training. In 5% of 
the studies, the authors described providing specific training 
in patient-centered approaches, respecting patients’ wishes, 
or helping patients set goals for their treatment.30,65,82,90,96 In 
one study, the authors explicitly stated that the HCP did not 
receive additional training.42
The role of the HCP in the intervention
When pharmacists were involved in the delivery of the inter-
vention, in 93% of cases, they carried out the full intervention. 
In contrast, it was more common for doctors to deliver only 
part of the intervention (64% of the studies in which doctors 
were involved), when compared with interventions delivered 
by pharmacists. The pharmacists often had a role as a patient 
educator, providing either tailored or fixed patient education, 
as well as making treatment recommendations. In the studies 
in which the doctors delivered the intervention, they gave 
advice and adjusted patients’ treatments, and also provided 
patient education. In four studies, the doctor delivered the 
intervention in collaboration with other HCPs.53,64,77,87
Tailored versus fixed interventions
Fifteen of the interventions were fixed. These included 
structured education,97,38 written information,96 mailed 
letters,77,95,111 videotapes, or telephone calls.51 In six studies, 
several methods were used.25,29,31,35,45 In one study, the patients 
were given a blood-pressure measuring device to take home 
and instructions on how to use it.84 Another study included 
a demonstration dose of sublingual nitroglycerin, for which 
the physician was present.72
Forty percent of the interventions were  tailored. 
These included tai lored pat ient  counsel ing, 22,58 
education,40,75,87,92,101,118 assessment and instructions,35,48,57 
or a combination of different approaches.67,78,109 In the studies 
in which the interventions were tailored, the HCP tailored 
the interventions based on patients’ needs, giving tailored 
information and advice36,46,50,120 and prioritizing the recom-
mendations based on the patients’ medical records.62,107 
Hederos et al64 used the concept of “concordance” (defined 
as reaching an agreement with parents of pediatric patients 
on how to look upon asthma and its management). They 
used this approach with the hypothesis that the parents would 
understand the advice and education better.  Personalized 
medication adherence plans, individual goal values, 
and identification of adherence  barriers were evaluated and 
used in five studies.28,48,52,61,82 In total, 14 studies explicitly 
reported using some method of tailoring the intervention 
by taking the patients’ own views into account rather than 
simply the HCP’s viewpoint.28,30,36,47,48,50,52,61,64,65,82,90,96,120
In 46% of the studies, it was unclear to what extent the 
interventions were tailored, as the interventions were not 
described in sufficient detail.
A greater proportion of studies carried out in the last 
15 years than older studies reported being tailored to patients’ 
needs (46% versus [vs] 6%). All the studies reporting the use 
of a more patient-centered concordant approach were carried 
out in the last 15 years. However, in the last 15 years, there 
was still a higher proportion of studies that did not describe 
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tailoring the intervention to individual patients’ needs than 
those that did.
effectiveness of the patient adherence support 
provided by pharmacists and doctors
Short-term versus long-term treatments
The effectiveness of interventions for studies focusing on 
short- and long-term treatments were similar. For short-
term treatments, interventions showed benefits in five 
studies,24,34,45,57,78 and one paper failed to show any benefits 
other than patient satisfaction with pharmacy service.108 For 
research focusing on long-term treatments, interventions 
showed benefits in 64 out of 79 (81%) studies. Consequently, 
15 studies failed to show any improvement.
A range of different outcomes was used in measuring 
the effectiveness of the adherence support provided. These 
included medication adherence, attending screening appoint-
ments, clinical outcomes, quality of life (QoL), medication 
knowledge, patient satisfaction, resource utilization, and cost 
analyses. The effects of the adherence intervention on these 
outcomes are summarized in Table 1.
Medication adherence
Medication adherence was measured in several different ways, 
including pill counts, serum concentrations, Medication Event 
Monitoring System, self-report, questionnaires, and pharma-
cists’ refill records. The interventions statistically significantly 
enhanced adherence in 68 studies. However, 35 interventions 
failed to show statistically significant improvement in 
 adherence. Some interventions did not result in a statistically 
significant change in adherence but did result in a statistically 
significant improvement in clinical outcomes – for example, 
blood pressure84 and fasting blood glucose.85 When differences 
in adherence were significant, a range of effect sizes was seen. 
Where adherence was  measured dichotomously and patients 
classified as either adhering or not adhering to treatment, in 
16 of 41 (40%) studies, the number of patients in the inter-
vention group adhering was double or more than double 
the number in the control group, with the remaining studies 
(25/41, 60%) showing more modest effects. When adherence 
was measured as an adherence rate, the mean adherence rates 
were between 3% and 20% greater in the intervention group 
than in the control group.
Inhaler technique was measured in six out of eleven 
studies regarding asthma, with improvement being demon-
strated in five of them.22,47,56,74,86 Inhaler technique was not 
measured in any of the studies regarding chronic obstructive 
pulmonary disease.
Screening appointments
Seven studies concerned adherence to cancer screenings. The 
authors recorded patients’ adherence to screening appoint-
ments to evaluate the effectiveness of the interventions. One 
study measured attitude toward the screening tests and did 
not find any statistically significant difference between the 
intervention group and control group.38 Of the six remain-
ing, five showed a statistically significant improvement in 
screening rates,29,35,77,110,111 and only one paper failed to show 
any improvement.95
Clinical outcomes
A range of clinical outcomes was assessed including: blood 
pressure, lipid levels, HbA
1c
 levels, severity of symptoms, 
and adverse drug events (ADEs).
Blood pressure was an outcome measure in 21 papers. Blood 
pressure was statistically significantly improved in 16 (76%) 
of them.10,32,36,41,48,61,67,69,71,84,87,88,96,107,113,120 Only five failed to 
show any statistically significant improvement.42,52,65,99,106
Table 1 effectiveness of the interventions
Outcome Papers measuring the  
outcome (n=103)
Papers showing statistically significant  
benefits/improvements, n (%)
Papers failing to show statistically  
significant benefits/improvements, n (%)
Medication adherence 103 68 (66) 35 (34)
Cancer screening rates 6 5 (83) 1 (17)
Quality of life 23 16 (70) 7 (30)
Blood pressure 21 16 (76) 5 (24)
Lipid values 13 7 (54) 6 (46)
HbA1c 9 8 (89) 1 (11)
Severity of symptoms 15 2 (13) 13 (87)
Adverse drug reactions 8 1 (13) 7 (87)
Medication knowledge  
and understanding
27 20 (74) 7 (26)
Resource utilization 19 3 (16) 16 (84)
Cost analyses 5 4 (80) 1 (20)
Abbreviation: HbA1c, hemoglobin A1c.
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Thirteen papers measured patients’ lipid levels, 
but the majority (seven) failed to show any significant 
difference.33,51,52,65,82,93,106
Nine papers measured HbA
1c
 levels.42,44,65,68,70,85,94,106 All 
but one of them65 demonstrated a statistically significant 
improvement in the intervention group.
Severity of symptoms was measured in 15 papers, and 
only two studies (13%) showed statistically significant 
changes in this outcome.83,89
Eight interventions used ADEs as an outcome measure. 
Seven (87%) of them failed to show any statistically sig-
nificant benefit, and the other one detected a statistically 
significant improvement in one arm of the study.89 Murray 
et al89 investigated the effect of adherence support on patients 
with complicated and uncomplicated heart failure and/or 
hypertension, and found a statistically significant reduction 
in ADEs in the complicated stratum but not in the uncom-
plicated stratum.
QoL
QoL was used as an outcome measure in 24 of the 
studies. Improvement was noted in nine (38%) of 
them27,67,68,83,99,100,104,109,112 and 15 (62%) failed to show any 
improvement.30,37,47,62,66,70,72,84,86,87,90,113,114,117,118
Medication knowledge and understanding
Medication knowledge and medication understand-
ing were used as measures in 27 studies. Medication 
knowledge was statistically signif icantly improved 
in 20 (74%) of the studies that used it as an outcome 
measure22,25–27,30,31,57,62,68,70,74,80,81,83,86,88,91,97,99,102,103,109,112,119 
and seven (26%) failed to show statistically significant 
improvement.26,30,62,86,103,109,119
Patient satisfaction
Sixteen papers measured patient satisfaction. In nine of 
the studies (56%), satisfaction increased as a result of 
the intervention,25,26,36,52,75,90,108,112,118 and, in seven studies 
(44%), patient satisfaction did not statistically significantly 
change.34,40,58,62,67,91,113
Resource utilization
A number of outcome measures were related to resource 
utilization, including hospitalization rates, visits to doctors, 
and visits to emergency rooms. Nineteen papers investigated 
patients’ resource utilization; a decrease was found in three 
(16%) studies,22,112,121 with the remaining 16 (84%) studies 
not finding any change.
Cost analysis
Six studies also did some form of cost analysis as a part 
of evaluating the effectiveness and feasibility of the 
interventions. One study42 was cost-effective and another 
showed a gain of 42.2 working days.64 Beaucage et al calcu-
lated that each intervention would cost US$3.74.34 Another 
study aimed to calculate total direct health care costs, but 
the variation in costs was too large for a comparison to be 
possible.90 In a fifth study, an economic evaluation of the 
intervention was conducted, determining that the interven-
tion group had a statistically significantly lower cost to the 
National Health Service (NHS) than the control.50 Zhang et al 
did not find any difference in cost of drugs or hospitalization 
between the intervention and control group.124
Discussion
evaluation: effectiveness of the role 
played by pharmacists and doctors  
in providing patient adherence support
Involving pharmacists and doctors in adherence support 
appears to improve outcomes to some extent, although the 
size of effect is sometimes small. Of the interventions involv-
ing pharmacists and doctors, 66% led to some improvements 
in medication adherence, while 73% led to some improve-
ments in clinical outcomes. These findings need to be viewed 
in the context of a high possibility of performance bias, 
because the nature of the interventions made it impossible 
to blind the participants. In addition, there is a possibility of 
reporting bias and of a higher proportion of interventions 
showing an effect being published than those not doing so.
The percentage of adherence interventions showing 
improvements in medication adherence and clinical out-
comes in this review was higher than in a Cochrane review 
of medication adherence interventions13 in which 44% were 
found to lead to improvements in medication adherence 
and 31% to improvements in clinical outcomes. In addition, 
improvement in adherence was higher than that found in 
another large-scale review.14 Our review focused on inter-
ventions involving doctors and pharmacists, while the other 
two reviews13,14 included all adherence interventions. This 
indicates that involving pharmacists and doctors in adher-
ence interventions may make them more effective. However, 
we are cautious with the interpretation of this finding, because 
the inclusion and exclusion criteria were not identical in the 
reviews. In addition, the studies covered by the reviews used 
many different types of interventions and different methods 
of measuring adherence and clinical outcomes, making direct 
comparisons impossible.
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It is of interest that in both our review and that of 
Morgado et al,18 who reviewed pharmacy interventions to 
enhance blood-pressure control and adherence to antihy-
pertensive therapy, more studies showed improvement in 
clinical outcomes than showed improvement in adherence. 
This contrasts with reviews of general adherence support 
programs13,14 (not necessarily involving a pharmacist), in 
which adherence was found to improve more frequently 
than clinical outcomes. The difference may be due to 
the multifaceted nature of interventions and the fact that 
pharmacists may make clinical recommendations as well 
as provide adherence support. The difference may also be 
due to the nonlinear relationship between adherence and 
clinical outcome in some conditions, and because some 
clinical outcomes, such as high blood pressure, are affected 
by factors that may not have been part of the intervention 
(such as exercise or diet).
Recommendations: ways to improve the 
delivery of patient adherence support
Recommendations for practice
Our review demonstrates that while the majority of adherence 
support provided by pharmacists and doctors leads to some 
improvements in outcomes, there is room to improve the pro-
vided support further. The successful features of adherence 
interventions that have been identified by previous research 
were not reported as being present in the majority of adher-
ence interventions provided by pharmacists and doctors.
Previous research has suggested that adherence support 
involving pharmacists that is tailored to individual needs, 
rather than being fixed, is more likely to be effective.15 In 
our review, while there was a trend toward more tailored 
approaches being used in the last 15 years, less than 50% of 
adherence support programs in the last 15 years were tailored 
to individual needs, with the remainder either being fixed or 
not reported in sufficient detail to determine if they had been 
tailored. We would therefore recommend increasing the level 
of tailoring of interventions to improve the delivery of patient 
adherence support.
In addition, taking a more concordant approach, where 
the aim is to formulate an agreed treatment plan between the 
HCP and patient rather than expecting the patient to follow 
the HCP’s instructions, has been shown to improve treatment 
outcomes.1 In our review, out of the 41 studies in which 
tailoring to patient need was reported, only 14 described a 
concordant approach whereby patients’ individual goal  values 
and identification of adherence barriers were evaluated and 
agreement reached. In the rest of the studies, the tailoring 
appeared to be a result of the HCP’s own view of the patient’s 
needs. We therefore recommend using a patient-centered 
approach and involving patients in decisions when tailoring 
adherence support.
Finally, the majority of studies did not describe any train-
ing for the HCPs involved. When training was reported, it 
was sometimes more focused on the specific clinical diseases 
involved rather than on how to give adherence support. We 
would recommend that HCPs receive specific training on 
how to develop a concordant approach with patients and 
formulate a joint treatment plan that meets patients’ own 
identified needs and that therefore may be more likely for 
patients to adhere to.
Recommendations for research
The majority of interventions were delivered by pharma-
cists rather than doctors. Evaluation of more adherence 
support programs involving doctors would inform this area 
of research, particularly as a previous review of adherence 
support in patients with cardiovascular problems and diabe-
tes suggested doctors were less effective than other HCPs 
in providing effective adherence support in these disease 
groups.20
A cost analysis economic evaluation was provided by 
very few of the studies. Cost analyses are important to 
evaluate the cost-effectiveness of interventions and would 
be helpful to incorporate into evaluations. The outcomes 
used in the studies included adherence to medication and 
adherence to attending screening appointments. However, 
use of these outcome measures makes the assumption 
that increased adherence is always a positive outcome. 
 Nonadherence may be an appropriate decision by the 
patient. None of the studies included a measure of concor-
dance or patient involvement in decision making. It would 
be appropriate to include such outcome measures – for 
example, the Leeds Attitude to Concordance scale125 – in 
future studies.
Limitations of the review
Due to the large volume of literature on adherence support 
strategies, our review only focused on the role of pharmacists 
and doctors in providing adherence support. Further reviews 
are needed on the role of other HCPs, especially nurses, in 
providing adherence support.
The search strategy for this review was broad and 
included adherence support for all treatments and  preventive 
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health care. This meant that we did not include search terms 
for specific treatments and preventive strategies such as 
“cancer screening” and may have missed some relevant 
studies in these areas. In addition, we excluded studies 
not written in English and did not use alterative names for 
“pharmacist”, such as “chemist”.
As with all reviews of adherence interventions, the 
definition of what is acceptable adherence is problematic. 
It is defined differently by different researchers and will 
vary from condition to condition. Relatedly, the differentia-
tion between people who miss occasional doses and those 
who take drug “holidays” is often not made. Again, as for 
all such reviews, the measurement of adherence in studies 
presents difficulties, as there is no gold standard for such 
measurement.
Conclusion
Adherence support programs involving pharmacists and 
 doctors appear to improve outcomes to some extent, although 
the size of effect is not always large. Their effectiveness may 
be increased by working with patients to tailor adherence 
strategies according to individual patient needs. A much 
greater volume of studies have evaluated the role of phar-
macists than the role of doctors; therefore, more research is 
needed to evaluate the role of doctors in providing adherence 
support.
Acknowledgments
This study had no specific source of funding. However, the 
Centre for Medication Safety and Service Quality is affili-
ated with the Centre for Patient Safety and Service Quality at 
Imperial College Healthcare NHS Trust, which is funded by 
the National Institute of Health Research (NIHR). This paper 
represents independent research supported by the Imperial 
NIHR Patient Safety Translational Research  Centre. The 
views expressed are those of the author(s) and not neces-
sarily those of the NHS, the NIHR, or the Department of 
Health. The work contributed by LE and CJ was funded by 
Atlantis Healthcare.
Disclosure
LE and CJ work for Atlantis Healthcare, which provides 
consulting services to pharmaceutical companies. This 
research was not funded by a pharmaceutical company. DKR 
is co-founder and academic advisor to Luto Research (http://
www.luto.co.uk), which develops, refines, and tests consumer 
health information. The authors declare no other conflicts of 
interest in this work.
References
 1. National Institute for Health and Clinical Excellence (NICE).  Medicines 
Adherence: Involving Patients in Decisions about  Prescribed  Medicines 
and Supporting Adherence. London: NICE; 2009. Available from: 
http://www.nice.org.uk/nicemedia/pdf/CG76NICEGuideline.pdf. 
Accessed May 9, 2014.
 2. Elliot R. Non-adherence to medicines: not solved but solvable. J Health 
Serv Res Policy. 2009;14(1):58–61.
 3. Trueman P, Lowson K, Blighe A, et al; York Health Economics Con-
sortium, School of Pharmacy, University of London. Evaluation of the 
Scale, Causes and Costs of Waste Medicines: Final Report. London: 
York Health Economics Consortium and School of Pharmacy, University 
of London; 2010. Available from: http://eprints. pharmacy.ac.uk/2605/1/
Evaluation_of_NHS_Medicines_Waste__web_ publication_version.
pdf. Accessed May 12, 2014.
 4. Capgemini Consulting. Patient Adherence: The Next Frontier in Patient 
Care; Vision and Reality. 9th ed. Paris: Capgemini Consulting; 2011. 
Available from: http://www.capgemini.com/resource-file-access/
resource/pdf/Patient_Adherence__The_Next_Frontier_in_Patient_
Care.pdf. Accessed May 12, 2014.
 5. DiMatteo MR. Variations in patients’ adherence to medical 
 recommendations: a quantitative review of 50 years of research. Med 
Care. 2004;42(3):200–209.
 6. Gao X, Nau DP, Rosenbluth SA, Scott V, Woodward C. The 
 relationship of disease severity, health beliefs and medica-
tion  adherence among HIV patients. AIDS Care. 2000;12(4): 
387–398.
 7. Gadkari AS, McHorney CA. Unintentional non-adherence to chronic 
prescription medications: how unintentional is it really? BMC Health 
Serv Res. 2012;12:98.
 8. World Health Organization (WHO). Adherence to Long-Term  Therapies: 
Evidence for Action. Geneva: WHO; 2003. Available from: http://www.
who.int/chp/knowledge/publications/adherence_full_report.pdf?ua=1. 
Accessed May 12, 2014.
 9. Horne R, Barber N, Weinman J, Elliott RA, Morgan M, Cribb A. 
 Concordance, adherence and compliance in medicine taking: a scop-
ing exercise. London: National Co-ordinating Centre for NHS Service 
Delivery and Organisation NCCSDO; 2006. Available from: http://www.
nets.nihr.ac.uk/__data/assets/pdf_file/0007/81394/ES-08-1412-076.pdf. 
Accessed June 4, 2014.
 10. Horne R, Keller I. Interventions to facilitate adherence. In: Horne 
R, Weinman J, Barber N et al (eds). Concordance, adherence and 
compliance in medicine taking: a conceptual map and research 
 priorities. National Co-ordinating Centre for NHS Service Deliver and 
 Organisation NCCSDO: London; 2006.
 11. Michie S, van Stralen MM, West R. The behaviour change wheel: 
a new method for characterising and designing behaviour change 
interventions. Implement Sci. 2011;6:42.
 12. Abraham C, Michie S. A taxonomy of behavior change techniques used 
in interventions. Health Psychol. 2008;27(3):379–387.
 13. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions 
for enhancing medication adherence. Cochrane Database Syst Rev. 
2008;(2):CD000011.
 14. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication 
adherence in chronic medical conditions: a systematic review. Arch 
Intern Med. 2007;167(6):540–550.
 15. Clifford S, Garfield S, Eliasson L, Barber N. Medication adherence 
and community pharmacy: a review of education, policy and research 
in England. Pharm Pract (Granada). 2010;8(2):77–88.
 16. Easthall C, Song F, Bhattacharya D. A meta-analysis of cognitive-based 
behaviour change techniques as interventions to improve medication 
adherence. BMJ Open. 2013;3(8).
 17. Rubio-Valera M, Serrano-Blanco A, Magdalena-Belio J, et al. 
 Effectiveness of pharmacist care in the improvement of adher-
ence to antidepressants: a systematic review and meta-analysis. 
Ann  Pharmacother. 2011;45(1):39–48.
Patient Intelligence 2014:6submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
40
Andersson et al
 18. Morgado MP, Morgado SR, Mendes LC, Pereira LJ, Castelo-Branco M. 
Pharmacist interventions to enhance blood pressure control and 
adherence to antihypertensive therapy: Review and meta-analysis. 
Am J Health Syst Pharm. 2011;68(3):241–253.
 19. Foppe van Mil JW, Schulz M. A review of pharmaceutical care 
in community pharmacy in Europe. Harvard Health Policy Rev. 
2006;7:155–168.
 20. Cutrona SL, Choudhry NK, Stedman M, et al. Physician effectiveness 
in interventions to improve cardiovascular medication adherence: 
a systematic review. J Gen Intern Med. 2010;25(10):1090–1096.
 21. Higgins JP, Altman DG, Sterne JA, editors; Cochrane Statistical 
 Methods Group and the Cochrane Bias Methods Group. Assessing risk 
of bias in included studies. In: Higgins JP, Green S, editors. Cochrane 
Handbook for Systematic Reviews of Interventions. V 5.1.0. Oxford: 
Cochrane Collaboration; 2011 [updated March]. Available from: 
http://handbook.cochrane.org/chapter_8/8_assessing_risk_of_bias_
in_included_studies.htm. Accessed May 12, 2014.
 22. Abdelhamid E, Awad A, Gismallah A. Evaluation of a hospital 
 pharmacy-based pharmaceutical care services for asthma patients. 
Pharm Pract (Granada). 2008;6(1):25–32.
 23. Adler DA, Bungay KM, Wilson IB, et al. The impact of a pharmacist 
intervention on 6-month outcomes in depressed primary care patients. 
Gen Hosp Psychiatry. 2004;26(3):199–209.
 24. Al-Eidan FA, McElnay, JC, Scott MG, McConnell JB. Management of 
Helicobacter pylori eradication – the influence of structured counselling 
and follow-up. Br J Clin Pharmacol. 2013;53(2):163–171.
 25. Al-Saffar N, Abdulkareem A, Abdulhakeem A, Salah AQ, Heba M. 
Depressed patients’ preferences for education about medications by 
pharmacists in Kuwait. Patient Educ Couns. 2008;72(1):94–101.
 26. Al-Saffar N, Deshmukh AA, Carter P, Adib SM. Effect of information 
leaflets and counselling on antidepressant adherence: open randomised 
controlled trial in a psychiatric hospital in Kuwait. Int J Pharm Pract. 
2005;13(2):123–131.
 27. Al Mazroui NR, Kamal MM, Ghabash NM, Yacout TA, Kole PL, 
McElnay JC. Influence of pharmaceutical care on health outcomes in 
patients with Type 2 diabetes mellitus. Br J Clin Pharmacol. 2009;67(5): 
547–557.
 28. Alsabbagh MW, Lemstra M, Eurich D, Wilson TW, Robertson P, 
Blackburn DF. Pharmacist intervention in cardiac  rehabilitation: 
a randomized controlled trial. J Cardiopulm Rehabil Prev. 2012;32(6): 
394–399.
 29. Aragones A, Schwartz MD, Shah NR, Gany FM. A randomized 
 controlled trial of a multilevel intervention to increase colorectal cancer 
screening among Latino immigrants in a primary care facility. J Gen 
Intern Med. 2010;25(6):564–567.
 30. Armour CL, Reddel HK, LeMay KS et al. Feasibility and effective-
ness of an evidence-based asthma service in Australian community 
pharmacies: a pragmatic cluster randomized trial. Journal of Asthma. 
2013;50(3):302–309.
 31. Ascione FJ, Shimp LA. The effectiveness of four education strategies 
in the elderly. Drug Intell Clin Pharm. 1984;18(11):926–931.
 32. Ashok KM, Elayaraja J, Shailaja K, Ramasamy C. Improving 
medication adherence and clinical outcomes of hypertensive patients 
through patient counseling. Res J Pharm Biol Chem Sci. 2011;2(3): 
231–241.
 33. Aslani P, Rose G, Chen TF, Whitehead PA, Krass I. A community 
pharmacist delivered adherence support service for dyslipidaemia. 
Eur J Public Health. 2011;21(5):567–572.
 34. Beaucage K, Lachance-Demers H, Ngo TT, et al. Telephone follow-up of 
patients receiving antibiotic prescriptions from community  pharmacies. 
Am J Health Syst Pharm. 2006;63(6):557–563.
 35. Bejes C, Marvel MK. Attempting the improbable: offering colorec-
tal cancer screening to all appropriate patients. Fam Pract Res J. 
1992;12(1):83–90.
 36. Blenkinsopp A, Phelan M, Bourne J, Dakhil N. Extended adherence 
support by community pharmacists for patients with hypertension: 
a randomised controlled trial. Int J Pharm Pract. 2000;8(3): 
165–175.
 37. Bouvy ML, Heerdink ER, Urquhart J, Grobbee DE, Hoes AW, Leufkens HG. 
Effect of a pharmacist-led intervention on diuretic compliance in 
heart failure patients: a randomized controlled study. J Card Fail. 
2003;9(5):404–411.
 38. Braun KL, Fong M, Kaanoi ME, Kamaka ML, Gotay CC.  Testing 
a culturally appropriate, theory-based intervention to improve 
 colorectal cancer screening among Native Hawaiians. Preventive Med. 
2005;40(6):619–627.
 39. Calvert SB, Kramer JM, Anstrom KJ, Kaltenbach LA, Stafford JA, 
Allen LaPointe NM. Patient-focused intervention to improve long-
term adherence to evidence-based medications: a randomized trial. 
Am Heart J. 2012;163(4):657–665.
 40. Capoccia KL, Boudreau DM, Blough DK, et al. Randomized trial of 
pharmacist interventions to improve depression care and outcomes in 
primary care. Am J Health Syst Pharm. 2004;61(4):364–372.
 41. Carter BL, Bergus GR, Dawson JD, et al. A cluster randomized trial to 
evaluate physician/pharmacist collaboration to improve blood pressure 
control. J Clin Hypertens. 2008;10(4):260–271.
 42. Chan CW, Siu SC, Wong CK, Lee VW. A pharmacist care program: 
positive impact on cardiac risk in patients with type 2 diabetes. 
J  Cardiovasc Pharmacol Ther. 2012;17(1):57–64.
 43. Chisholm MA, Mulloy LL, Jagadeesan M, DiPiro JT. Impact of clinical 
pharmacy services on renal transplant patients’ compliance with immu-
nosuppressive medications. Clin Transplant. 2001;15(5):330–336.
 44. Choe HM, Mitrovich S, Dubay D, Hayward RA, Krein SL, Vijan S. 
Proactive case management of high-risk patients with type 2 diabetes 
mellitus by a clinical pharmacist: a randomized controlled trial. Am J 
Manag Care. 2005;11(4):253–260.
 45. Clark PM, Karagoz T, Apikoglu-Rabus S, Izzettin FV. Effect of 
pharmacist-led patient education on adherence to tuberculosis treatment. 
Am J Health Syst Pharm. 2007;64(5):497–506.
 46. Clifford S, Barber N, Elliott R, Hartley E, Horne R. Patient-centred 
advice is effective in improving adherence to medicines. Pharm 
World Sc. 2006;28(3):165–170.
 47. Cordina M, McElnay JC, Hughes CM. Assessment of a community 
pharmacy-based program for patients with asthma. Pharmacotherapy. 
2001;21(10):1196–1203.
 48. Criswell TJ, Weber CA, Xu Y, Carter BL. Effect of self-efficacy and 
social support on adherence to antihypertensive drugs.  Pharmacotherapy. 
2010;30(5):432–441.
 49. De Tullio PL, Kirking DM, Arslanian C, Olson DE. Compliance 
 measure development and assessment of theophylline therapy in 
ambulatory patients. J Clin Pharm Ther. 1987;12(1):19–26.
 50. Elliott RA, Barber N, Clifford S, Horne R, Hartley E. The cost effec-
tiveness of a telephone-based pharmacy advisory service to improve 
adherence to newly prescribed medicines. Pharm World Sc. 2008;30(1): 
17–23.
 51. Eussen SR, van der Elst ME, Klungel OH, et al. A pharmaceutical 
care program to improve adherence to statin therapy: a randomized 
controlled trial. Ann Pharmacother. 2010;44(12):1905–1913.
 52. Evans CD, Eurich DT, Taylor JG, Blackburn DF. The Collaborative 
Cardiovascular Risk Reduction in Primary Care (CCARP) study. 
Pharmacotherapy. 2010;30(8):766–775.
 53. Farber HJ, Oliviera L. Trial of an asthma education program in an 
inner-city pediatric emergency department. Pediatr Asthma Allergy 
Immunol. 2004;17(2):107–115.
 54. Faulkner MA, Wadibia EC, Lucas BD, Hilleman DE. Impact of 
pharmacy counseling on compliance and effectiveness of combina-
tion lipid-lowering therapy in patients undergoing coronary artery 
revascularization: a randomized, controlled trial. Pharmacotherapy. 
2000;20(4):410–416.
 55. Finley PR, Rens HR, Pont JT, et al. Impact of a collaborative care model 
on depression in a primary care setting: a randomized controlled trial. 
Pharmacotherapy. 2003;23(9):1175–1185.
 56. García-Cárdenas V, Sabater-Hernández D, Kenny P, Martínez-Martínez 
F, Faus MJ, Benrimoj SI. Effect of a pharmacist intervention on 
asthma control. A cluster randomised trial. Respiratory Medicine. 
2013;107(9):1346–1355.
Patient Intelligence 2014:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
41
Delivery of patient adherence support
 57. Garnett WR, Davis LJ, McKenney JM, Steiner KC. Effect of telephone 
follow-up on medication compliance. Am J Hosp Pharm. 1981;38(5): 
676–679.
 58. Geurts MM, Pot JL, Schepers EH, et al. The evaluation of an intervention 
based on the application of patient self-completion concordance forms 
in Dutch community pharmacies and the effect on adherence to chronic 
medication. Patient Educ Couns. 2010;78(1):85–90.
 59. Grant RW, Devita NG, Singer DE, Meigs JB. Improving adherence 
and reducing medication discrepancies in patients with diabetes. Ann 
Pharmacother. 2003;37(7–8):962–969.
 60. Grymonpre RE, Williamson DA, Montgomery PR. Impact of a phar-
maceutical care model for non-institutionalised elderly: results of a 
randomised, controlled trial. Int J Pharm Pract. 2001;9(4)235–241.
 61. Hamann J, Cohen R, Leucht S, Busch R, Kissling W. Shared decision 
making and long-term outcome in schizophrenia treatment. J Clin 
Psychiatry. 2007;68(7)992–997.
 62. Hanlon JT, Weinberger M, Samsa GP, et al. A randomized, controlled 
trial of a clinical pharmacist intervention to improve inappropriate 
prescribing in elderly outpatients with polypharmacy. Am J Med. 
1996;100(4):428–437.
 63. Hawkins DW, Fiedler FP, Douglas HL, Eschbach RC. Evaluation of 
a clinical pharmacist in caring for hypertensive and diabetic patients. 
Am J Hosp Pharm. 1979;36(10):1321–1325.
 64. Hederos C. Group discussions with parents have long-term positive 
effects on the management of asthma with good cost-benefit. Acta 
Paediatr. 2005;94(5):602–608.
 65. Heisler M, Hofer TP, Schmittdiel JA, et al. Improving blood pressure 
control through a clinical pharmacist outreach program in patients 
with diabetes mellitus in 2 high-performing health systems: the adher-
ence and intensification of medications cluster randomized, controlled 
pragmatic trial. Circulation. 2012;125(23):2863–2872.
 66. Holland R, Brooksby I, Lenaghan E, et al. Effectiveness of visits from 
community pharmacists for patients with heart failure: HeartMed 
randomised controlled trial. BMJ. 2007;334(7603):1098.
 67. Hunt JS, Siemienczuk J, Pape G, et al. A randomized controlled trial of 
team-based care: impact of physician-pharmacist collaboration on uncon-
trolled hypertension. J Gen Intern Med. 2008;23(12):1966–1972.
 68. Iram M, Shobha Rani RH, Pais N. Impact of patient counseling and 
education of diabetic patients in improving their quality of life. Arch 
Pharm Pract. 2010;1(2):18–22.
 69. Jacobs M, Sherry PS, Taylor LM, Amato M, Tataronis GR, Cushing G. 
 Pharmacist Assisted Medication Program Enhancing the Regulation 
of Diabetes (PAMPERED) study. J Am Pharm Assoc. 2012;52(5): 
613–621.
 70. Jarab AS, Alqudah SG, Khdour M, Shamssain M, Mukattash TL. Impact 
of pharmaceutical care on health outcomes in patients with COPD. 
Int J Clin Pharm. 2012;34(1):53–62.
 71. Jarab AS, Alqudah SG, Mukattash TL, Shattat G, Al-Qirim T. 
 Randomized controlled trial of clinical pharmacy management of 
patients with type 2 diabetes in an outpatient diabetes clinic in Jordan. 
J Manag Care Pharm. 2012;18(7):516–526.
 72. Kelly JM. Sublingual nitroglycerin: improving patient compliance with 
a demonstration dose. J Am Board Fam Pract. 1988;1(4):251–254.
 73. Klein A, Otto G, Krämer I. Impact of a pharmaceutical care program 
on liver transplant patients’ compliance with immunosuppressive 
medication: a prospective, randomized, controlled trial using electronic 
monitoring. Transplantation. 2009;87(6):839–847.
 74. Kumar DS, Adepu R, Parthasarathi G, Mahesh PA. Impact of 
 community pharmacist provided patient education in asthma patients 
on treatment outcomes – a study. Indian Journal of Pharmaceutical 
Education and Research. 2009;43(2):125–133.
 75. López Cabezas C, Falces Salvador C, Cubí Quadrada D, et al. 
 Randomized clinical trial of a postdischarge pharmaceutical care 
 program vs regular follow-up in patients with heart failure. Farm Hosp. 
2006;30(6):328–335. English and Spanish.
 76. Lai PS, Chua SS, Chew YY, Chan SP. Effects of pharmaceutical care 
on adherence and persistence to bisphosphonates in postmenopausal 
osteoporotic women. J Clin Pharm Ther. 2011;36(5):557–567.
 77. Lantz PM, Stencil D, Lippert MT, Beversdorf S, Jaros L, Remington PL. 
Breast and cervical cancer screening in a low-income managed care 
sample: the efficacy of physician letters and phone calls. Am J Public 
Health. 1995;85(6):834–836.
 78. Lee M, Kemp JA, Canning A, Egan C, Tataronis G, Farraye FA. 
A randomized controlled trial of an enhanced patient  compliance pro-
gram for Helicobacter pylori therapy. Arch Intern Med. 1999;159(19): 
2312–2316.
 79. Lee SS, Cheung PY, Chow MS. Benefits of individualized counseling 
by the pharmacist on the treatment outcomes of hyperlipidemia in 
Hong Kong. J Clin Pharmacol. 2004;44(6):632–639.
 80. Lim WS, Low HN, Chan SP, Chen HN, Ding YY, Tan TL. Impact of a 
pharmacist consult clinic on a hospital-based geriatric outpatient clinic 
in Singapore. Ann Acad Med Singapore. 2004;33(2):220–227.
 81. Lipton HL, Bird JA. The impact of clinical pharmacists’ consultations 
on geriatric patients’ compliance and medical care use: a randomized 
controlled trial. Gerontologist. 1994;34(3):307–315.
 82. Ma Y, Ockene IS, Rosal MC, Merriam PA, Ockene JK, Gandhi PJ. 
Randomized Trial of a Pharmacist-Delivered Intervention for Improving 
Lipid-Lowering Medication Adherence among Patients with Coronary 
Heart Disease. Cholesterol. 2010;2010:383281.
 83. McLean W, Gillis J, Waller R. The BC Community Pharmacy 
Asthma Study: A study of clinical, economic and holistic outcomes 
influenced by an asthma care protocol provided by specially trained 
community pharmacists in British Columbia. Can Respir J. 2003;10(4): 
195–202.
 84. Mehos BM, Saseen JJ, MacLaughlin EJ. Effect of pharmacist inter-
vention and initiation of home blood pressure monitoring in patients 
with uncontrolled hypertension. Pharmacotherapy. 2000;20(11): 
1384–1389.
 85. Mehuys E, Van BL, De BL et al. Effectiveness of a community phar-
macist intervention in diabetes care: a randomized controlled trial. 
J Clin Pharm Ther. 2011;36(5):602–613.
 86. Mehuys E, Van Bortel L, De Bolle L, et al. Effectiveness of pharmacist 
intervention for asthma control improvement. Eur Respir J. 2008;31(4): 
790–799.
 87. Mohammadi E, Abedi HA, Jalali F, Gofranipour F, Kazemnejad A. 
Evaluation of ‘partnership care model’ in the control of hypertension. 
Int J Nurs Pract. 2006;12(3):153–159.
 88. Morgado M, Rolo S, Castelo-Branco M. Pharmacist intervention 
 program to enhance hypertension control: a randomised controlled 
trial. Int J Clin Pharm. 2011;33(1):132–140.
 89. Murray MD, Ritchey ME, Wu J, Tu W. Effect of a pharmacist on adverse 
drug events and medication errors in outpatients with cardiovascular 
disease. Arch Intern Med. 2009;169(8):757–763.
 90. Murray MD, Young J, Hoke S, et al. Pharmacist intervention to improve 
medication adherence in heart failure: a randomized trial. Ann Intern 
Med. 2007;146(10):714–725.
 91. Nazareth I, Burton A, Shulman S, Smith P, Haines A, Timberal H. 
A pharmacy discharge plan for hospitalized elderly patients – a random-
ized controlled trial. Age Ageing. 2001;30(1):33–40.
 92. Noureldin M, Plake KS, Morrow DG, Tu W, Wu J, Murray MD. Effect 
of health literacy on drug adherence in patients with heart failure. 
Pharmacotherapy. 2012;32(9):819–826.
 93. Peterson GM, Fitzmaurice KD, Naunton M, Vial JH, Stewart K, Krum H. 
Impact of pharmacist-conducted home visits on the outcomes of lipid-
lowering drug therapy. J Clin Pharm Ther. 2004;29(1):23–30.
 94. Phumipamorn S, Pongwecharak J, Soorapan S, Pattharachayakul S. 
Effects of the pharmacist’s input on glycaemic control and cardiovascu-
lar risks in Muslim diabetes. Prim Care Diabetes. 2008;2(1):31–37.
 95. Pierce M, Lundy S, Palanisamy A, Winning S, King J. Prospective 
randomised controlled trial of methods of call and recall for cervical 
cytology screening. BMJ. 1989;299(6692):160–162.
 96. Pladevall M, Brotons C, Gabriel R, et al; Writing Committee on behalf 
of the COM99 Study Group. Multicenter cluster-randomized trial of 
a  multifactorial intervention to improve antihypertensive medication 
adherence and blood pressure control among patients at high cardiovas-
cular risk (the COM99 study). Circulation. 2010;122(12): 1183–1191.
Patient Intelligence
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/patient-intelligence-journal
Patient Intelligence is an international, peer-reviewed, open access journal that 
characterizes and measures the central role of patient behavior and intention in 
optimizing healthcare management in all areas of disease and complaint types. An 
improved understanding of patient intelligence coupled with predictive analysis 
helps an organization contribute more effectively to achieving better outcomes. 
The journal is characterized by the rapid reporting of reviews, original research, 
methodologies, analytics, modeling, clinical studies and patient surveys across 
all disease areas. The manuscript management system is completely online and 
includes a very quick and fair peer-review system. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Patient Intelligence 2014:6submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
42
Andersson et al
 97. Polack J, Jorgenson D, Robertson P. Evaluation of different  methods 
of providing medication-related education to patients following 
 myocardial infarction. Can Pharm J. 2008;141(4):241–247.
 98. Qureshi NN1, Hatcher J, Chaturvedi N, Jafar TH; Hypertension 
Research Group. Effect of general practitioner education on adherence 
to antihypertensive drugs: cluster randomised controlled trial. BMJ. 
2007;335(7626):1030.
 99. Ramanath K, Balaji D, Nagakishore Ch, Kumar SM, Bhanuprakash M. 
A study on impact of clinical pharmacist interventions on medication 
adherence and quality of life in rural hypertensive patients. J Young 
Pharm. 2012;4(2):95–100.
 100. Ramanath KV, Venkappa KR. Study the impact of clinical pharmacist 
provided patient counseling on hypertension management in rural 
Indian population. Arch Pharm Pract. 2013;4(1):28–34.
 101. Rathbun RC, Farmer KC, Stephens JR, Lockhart SM. Impact of an 
adherence clinic on behavioral outcomes and virologic response in 
treatment of HIV infection: a prospective, randomized, controlled 
pilot study. Clin Ther. 2005;27(2):199–209.
 102. Rickles NM, Svarstad BL, Statz-Paynter JL, Taylor LV, Kobak KA. 
Improving patient feedback about and outcomes with antidepressant 
treatment: a study in eight community pharmacies. J Am Pharm Assoc. 
2006;46(1):25–32.
 103. Rickles NM, Svarstad BL, Statz-Paynter JL, Taylor LV, Kobak KA. 
Pharmacist telemonitoring of antidepressant use: effects on 
 pharmacist-patient collaboration. J Am Pharm Assoc. 2005;45(3): 
344–353.
 104. Sadik A, Yousif M, McElnay JC. Pharmaceutical care of patients with 
heart failure. Br J Clin Pharmacol. 2005;60(2)183–193.
 105. Sathvik BS, Karibasappa MV, Nagavi BG. Self-reported medication 
adherence pattern of rural Indian patients with hypertension. Asian 
Journal of Pharmaceutical and Clinical Research. 2013;6(Suppl 1): 
49–52.
 106. Shah M, Norwood CA, Farias S, Ibrahim S, Chong PH, Fogelfeld L. 
 Diabetes transitional care from inpatient to outpatient setting:  pharmacist 
discharge counseling. J Pharm Pract. 2013;2(2):120–124.
 107. Sookaneknun P, Richards RM, Sanguansermsri J, Teerasut C. 
 Pharmacist involvement in primary care improves hypertensive patient 
clinical outcomes. Ann Pharmacother. 2004;38(12):2023–2028.
 108. Stevens VJ, Shneidman RJ, Johnson RE, Boles M, Steele PE, Lee NL. 
Helicobacter pylori eradication in dyspeptic primary care patients: 
a randomized controlled trial of a pharmacy intervention. West J Med. 
2002;17(2):92–96.
 109. Sturgess IK, McElnay JC, Hughes CM, Crealey G. Community 
 pharmacy based provision of pharmaceutical care to older patients. 
Pharm World Sci. 2003;25(5):218–226.
 110. Thompson RS, Michnich ME, Gray J, Friedlander L, Gilson B. 
Maximizing compliance with hemoccult screening for colon cancer 
in clinical practice. Med Care. 1986;24(10):904–914.
 111. Turner KM, Wilson BJ, Gilbert FJ. Improving breast screening uptake: 
persuading initial non-attenders to attend. J Med Screen. 1994;1(3): 
199–202.
 112. Varma S, McElnay JC, Hughes CM, Passmore AP, Varma M. 
 Pharmaceutical care of patients with congestive heart failure:  interventions 
and outcomes. Pharmacotherapy. 1999;19(7):860–869.
 113. Vivian EM. Improving blood pressure control in a pharmacist-managed 
hypertension clinic. Pharmacotherapy. 2002;22(12):1533–1540.
 114. Volume CI, Farris KB, Kassam R, Cox CE, Cave A. Pharmaceutical 
care research and education project: patient outcomes. J Am Pharm 
Assoc (Wash). 2001;41(3):411–420.
 115. Vuong T, Marriott JL, Kong DC, Siderov J. Implementation of a 
community liaison pharmacy service: a randomised controlled trial. 
Int J Pharm Pract. 2008;16(3):127–135.
 116. Wandless I, Whitmore J. The effect of counseling by a  pharmacist on 
drug compliance in elderly patients. J Clin Hosp Pharm. 1981;6(1): 
51–56.
 117. Wang KY, Chian CF, Lai HR, Tarn YH, Wu CP. Clinical pharmacist 
counseling improves outcomes for Taiwanese asthma patients. Pharm 
World Sci. 2010;32(6):721–729.
 118. Weinberger M, Murray MD, Marrero DG, et al. Effectiveness of phar-
macist care for patients with reactive airways disease: a  randomized 
controlled trial. JAMA. 2002;288(13):1594–1602.
 119. Williford SL, Johnson DF. Impact of pharmacist counseling on  medication 
knowledge and compliance. Mil Med. 1995;160(11):561–564.
 120. Wong MC, Liu KQ, Wang HH, et al. Effectiveness of a pharmacist-led 
drug counseling on enhancing antihypertensive adherence and blood 
pressure control: a randomized controlled trial. J Clin Pharmacol. 
2013;53(7):753–761.
 121. Wu JY, Leung WY, Chang S, et al. Effectiveness of telephone 
 counselling by a pharmacist in reducing mortality in patients 
receiving polypharmacy: randomised controlled trial. BMJ. 2006; 
333(7567):522.
 122. Young HN, Havican SN, Griesbach S, Thorpe JM, Chewning BA, 
Sorkness CA. Patient and phaRmacist telephonic encounters (PARTE) 
in an underserved rural patient population with asthma: results of a 
pilot study. Telemed J E Health. 2012;18(6):427–433.
 123. Zerafa N, Zarb Adami M, Galea J. Impact of drugs counselling by an 
undergraduate pharmacist on cardiac surgical patient’s compliance to 
medicines. Pharmacy Practice (Granada). 2011;9(3):156–161.
 124. Zhang C, Zhang L, Huang L, Luo R, Wen J. Clinical pharmacists 
on medical care of pediatric inpatients: a single-center randomized 
controlled trial. PLoS ONE. 2012;7(1):e30856.
 125. Knapp P, Raynor DK, Thistlethwaithe JE, Jones MB. A questionnaire 
to measure health practitioners’ attitudes to partnership in medicine 
taking: LATCon II. Health Expect. 2009;12(2):175–186.
